Breast Cancer – HER 2 Negative (ABC Trial)

Sponsor: Easton Cooperative Group (ECOG)

Study:  A011502

Phase III

A randomized Phase III Double Blinded Placebo Controlled of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer

Eligibility Criteria:

  • Women or men with node positive, HER2 negative, Stage II or III breast cancer or high-risk node negative (defined as ER negative and tumor size>2) within one year of diagnosis and free of recurrence
  • You have completed chemotherapy and/or radiation at least 2 months ago
  • You have not regularly taken aspirin 5 or more days a week in the past year, including low -dose (baby) aspirin
  • You are between 18 and 70 years old

Participation Involves:

  • You will be randomly (at chance) assigned to either a 300mg aspirin pill or a placebo once a day over 5 years
  • Blood and urine samples at the beginning of the study and at 2 years
  • Access to your tumor samples if available
  • A few survey questions on your general health and lifestyle at the beginning of the study and at 2 years

To learn more about available clinical research trials contact:

Deborah Brunetti, RN, CRC
Hunterdon Regional Cancer Center – Research Department
2100 Wescott Drive
Flemington, NJ 08822
908-237-2330 option #3